Clinical trials
Chronic Myeloid Leukemia, Chronic Phase clinical trials
Below are recruiting chronic myeloid leukemia, chronic phase clinical trials, each written for real people, not researchers. We’re tracking 116 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06163430RecruitingPhase 1/Phase 2
Study of MK-4208 for chronic myeloid leukemia
This trial tests a new pill that may help people with chronic myeloid leukemia (CML) when other treatments have stopped working or caused side effects. It might offer another option for controlling the disease.
Birmingham, AlabamaAges 18 years+ - NCT01281735Recruiting
Study for children with Philadelphia-positive chronic leukemia
This trial is for children under 18 who have chronic myeloid leukemia (CML) with specific lab findings (Philadelphia-positive and/or BCR-ABL positive). It aims to test a treatment approach in pediatric patients with this form of CML.
North Adelaide, South AustraliaAges Up to 18 years - NCT07661095RecruitingPhase 1
Study of CRD3874-SI for relapsed or refractory AML
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
Basking Ridge, New JerseyAges 18 years+ - NCT06643962Recruiting
Venetoclax plus strong chemo for AML with slow blast clearance
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
Nantong, JiangsuAges 18–70 - NCT07549516Recruiting
Asciminib for chronic myeloid leukemia in germany
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
Baden-Baden, Baden-WurttembergAges 18–100 - NCT07383298Enrolling by invitation
Lower dose of olverembatinib for chronic myeloid leukemia
This study looks at whether lowering the dose of olverembatinib (from 30 or 40 mg to 20 mg every other day) keeps working well for people with chronic myeloid leukemia who have already had a good response. It aims to see if a lower dose can still control the cancer while possibly reducing side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06453902RecruitingPhase 2
Testing TGRX-678 for advanced CML after prior treatments
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
Beijing, Beijing MunicipalityAges 18 years+ - NCT07375355Recruiting
A study of Scemblix for newly diagnosed chronic myeloid leukemia in China
This study looks at how well the medicine Scemblix (asciminib) works for people in China who have just been diagnosed with a certain type of leukemia (chronic myeloid leukemia in chronic phase). It aims to see if starting this treatment soon after diagnosis is effective and safe.
Wuhan, HubeiAges 18–99 - NCT05190471RecruitingPhase 1
Study drug for adults with AML that did not respond or returned
This Phase 1 study tests BP1002 in adults with acute myeloid leukemia (AML) that is refractory (not responding) or relapsed (coming back). It’s early-stage, aiming to find a safe dose and see if the treatment can help people with limited options.
La Jolla, CaliforniaAges 18 years+ - NCT07303660RecruitingPhase 1
Study of Lonitoclax and azacitidine for AML
This trial tests a new drug called Lonitoclax combined with azacitidine for people with AML that has come back or not responded to prior treatment. The study will see if the combination is safe and can help control the leukemia.
Moscow, MoscowAges 18 years+ - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT07269470RecruitingPhase 2
Dasatinib plus ropeginterferon for new CML
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
Houston, TexasAges 18 years+ - NCT05282108Recruiting
Generic imatinib vs Glivec for newly diagnosed CML
This trial studies whether a generic version of imatinib (Carcemia®) works as well and is as safe as Glivec® in real-life care for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). It may help confirm that the generic option is effective for controlling the disease.
CairoAges 18 years+ - NCT06118788RecruitingPhase 1/Phase 2
BG1805 for relapsed or refractory acute myeloid leukemia
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
Guangzhou, GuangdongAges 18–70 - NCT06355583RecruitingPhase 2
Gut bacteria transplant before stem cell transplant
This trial tests whether giving a transplant of healthy gut bacteria (fecal microbiota transplant) before a stem cell transplant can improve outcomes for people with certain blood cancers or bone marrow disorders.
Birmingham, EnglandAges 18 years+ - NCT07071155RecruitingEarly Phase 1
Momelotinib with a hypomethylating agent for certain blood cancers
This trial tests a combination of two drugs, momelotinib and a hypomethylating agent, for people with certain slow-growing blood cancers. If you have a diagnosis like chronic myelomonocytic leukemia or chronic neutrophilic leukemia and have an enlarged spleen, this study might be exploring a new treatment option for you.
Baltimore, MarylandAges 18–100 - NCT07061145Recruiting
TKI treatment and erectile dysfunction in men with CML
This study looks at whether tyrosine kinase inhibitors (TKIs), a common treatment for chronic myeloid leukemia (CML), are linked to erectile dysfunction in men. It aims to help patients and doctors understand possible side effects.
Reggio Emilia, REAges 18–75 - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT06119269Recruiting
Ponatinib for chronic phase CML
This study looks at how the drug ponatinib works in people with chronic phase CML. It aims to understand how the body handles the drug and if it helps control the leukemia.
CagliariAges 18 years+ - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Stanford, CaliforniaAges 18 years+ - NCT06787144RecruitingPhase 1
Studying ELVN-001 for Japanese adults with CML
This trial tests a new drug called ELVN-001 for people with chronic myeloid leukemia (CML) who have not responded to or could not take at least two prior treatments. It's for Japanese patients, including those with a specific genetic change (T315I mutation). The goal is to see if ELVN-001 can help control the leukemia.
Akita, AkitaAges 18 years+ - NCT06409936RecruitingPhase 2
Early use of asciminib for new CML patients
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
BarcelonaAges 18 years+ - NCT06817720RecruitingPhase 2
Olverembatinib for newly diagnosed chronic phase CML
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
Houston, TexasAges 18 years+ - NCT06811233RecruitingPhase 2
Metal detox during AML treatment
This trial tests whether monitoring and rebalancing metals in the body can help improve treatment for adults with acute myeloid leukemia (AML) or related conditions. It's for patients who are getting their first or second round of therapy and aren't yet in remission.
Houston, TexasAges 18 years+
Hear when a new Chronic Myeloid Leukemia, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic myeloid leukemia, chronic phase?
- Yes. Clin2 currently lists 116 recruiting chronic myeloid leukemia, chronic phase studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic myeloid leukemia, chronic phase trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic myeloid leukemia, chronic phase trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.